Discovery of new adjuvants for oral vaccine formulations

CASTRO, CELESTE PUEBLAS; CORIA, LORENA; BRUNO LAURA; PASQUEVICH KARINA; CASSATARO JULIANA

Buenos Aires

Congreso; Reunión Anual de Sociedades de Biociencia SAIC ? SAI ? AAFE ? NANOMED-AR; 2021

SAIC ? SAI ? AAFE ? NANOMED-AR

In our laboratory, we have shown that U-Omp19 would be an ideal mucosal adjuvant because it can inhibit gastrointestinal proteases while it induces adaptive immune responses. To our knowledge there are no other published reports describing the use of protease inhibitors from bacteria as immune vaccine adjuvants.Based on these previous results, we studied if other microbial protease inhibitors also have adjuvant activity. After an in-silico screening using MEROPS database plus literature, we have selected 11 protease inhibitors present in human pathogenic microorganisms representing different families of protease inhibitors.We made a screening based on 3 different selection criteria: i) purification yield, ii) protease inhibitor activity against gastrointestinal proteases and iii) immunostimulatory properties. Our results indicate that 5 putative protease inhibitors can inhibit the protease activity of gastrointestinal proteases and pancreatin extract (p